semaglutide and cardiovascular outcomes in obesity Beyond obesity: Novo's SELECT re-defines risk management Evaluating the Cardiovascular Benefits of
Description
2014Sep;15(3):181187
If you hit a plateau after 3-6 months, dont be discouraged this is normal
Guidelines should be updated as new antiobesity drugs and more data become available
This testing informs whether semaglutide alone, or combination therapy with tirzepatide, aligns better with your genetic predispositions for weight loss and metabolic controlensuring proper medication selection and dosing strategy from the start
